Table 3.

Trials on Intermittent Preventive Treatment in pregnancy

Country	Year	Trial arms	N	Findings
Uganda[110]	2004–2007	SP vs SP+ITN vs ITN+placebo	5775	No differences between treatment arms
Mali[100]	2006–2008	SP 3 vs 2 doses	814	SP3 vs SP2: 50% reduction in placental parasitaemia, LBW, pre-term births
Ghana[107]	2004–2007	SP, AQ, SP+AQ	3643	No difference peripheral parasitaemia, adverse events more frequent with AQ
Benin[109]	2005–2008	MQ, SP	1601	No difference in LBW, MQ more efficacious than SP in preventing malaria, MQ had more adverse events
Burkina Faso [37] **	2004–2006	SP	1441	SP2 vs SP0c At delivery, 96% reduction placental infection, increase PCV, reduction LBW in primigravidae
Benin[108]	2005–2006	CQ, SP	1699	SP vs CQ decreased LBW by 50%, placental infection by 80%
Mozambique[101]	2003–2005	SP, PBa	1030	No reduction of LBW, anaemia at delivery and placenta malaria; 40% reduction incidence of clinical malaria
Mozambique*[57]	2003–2005	SP, PBa	1030	PE 61.3% neonatal mortality
Ghana[26]	2007–2008	IPTp-SP, IST	3333	No difference between study arms but increase in Hb after intervention
Nigeria[102]	2003–2005	SP, CQ	352	PE against anaemia: 49.5 SP vs CQ
Nigeria[103]	2002	SP, CQ-P	500	SP better than CQ-P
Mozambique[104]	2001–2002	SP vs??	600	Parasite prevalence SP 6.3% vs 13.6%, 2.4 vs 13.3, high loss to follow-up

^aPB=placebo, SP=sulfadoxine-pyrimethamine, AQ=amodiaquine, CQ=chloroquine, P=pyrimethamine;

^b12–28 weeks;

^cSP2=2 doses of SP, SP0=no dose of SP;

^*maternal and birth outcomes up to 8 weeks have been reported in [101];

^**community trial;

PE=parasitological efficacy; IST: Intermittent Screening and Treatment